SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-8.6M $-21.3M $67.0M $-62.8M $-32.9M $-55.2M $-53.7M $-12.5M
Depreciation & Amortization — $0 $580.0K $606.0K $379.0K $111.0K — —
Depreciation — — — — $200.0K $200.0K $111.0K $53.0K
Amortization — — $400.0K $700.0K $200.0K — — —
Stock-Based Compensation $2.9M $3.3M $2.6M $3.7M $2.1M — — —
Net Cash from Operating Activities $-5.3M $-24.0M $60.2M $-79.9M $-54.6M $-49.4M $-38.1M $-28.3M
Investing Activities
Capital Expenditures — — — — $0 $4.0K $0 $565.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $24.3M $6.2M $-34.9M $-27.4M $-1.2M $6.5M $26.2M $-803.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-14.2M $-139.0K $-36.7M $48.6M $67.1M $94.0M $42.3M $29.4M
Net Change in Cash — — — — — — — —
Free Cash Flow — — — — $-54.6M $-49.4M $-38.1M $-28.9M
← Newer Page 1 of 2 Older →